Effect of apigenin on whole transcriptome profile of TNFα‑activated MDA‑MB‑468 triple negative breast cancer cells
- Authors:
- David Bauer
- Elizabeth Mazzio
- Aaron Hilliard
- Ebenezer T. Oriaku
- Karam F. A. Soliman
-
Affiliations: Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA - Published online on: January 22, 2020 https://doi.org/10.3892/ol.2020.11327
- Pages: 2123-2132
-
Copyright: © Bauer et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Yoshimura T: The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments. Cytokine. 98:71–78. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lee S, Lee E, Ko E, Ham M, Lee HM, Kim ES, Koh M, Lim HK, Jung J, Park SY and Moon A: Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9. Cancer Lett. 437:25–34. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Porrello A, Leslie PL, Harrison EB, Gorentla BK, Kattula S, Ghosh SK, Azam SH, Holtzhausen A, Chao YL, Hayward MC, et al: Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. Nat Commun. 9:19882018. View Article : Google Scholar : PubMed/NCBI | |
|
Mandal PK, Biswas S, Mandal G, Purohit S, Gupta A, Majumdar Giri A, Roy Chowdhury S and Bhattacharyya A: CCL2 conditionally determines CCL22-dependent Th2-accumulation during TGF-beta-induced breast cancer progression. Immunobiology. 223:151–161. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshimura T: The chemokine MCP-1 (CCL2) in the host interaction with cancer: A foe or ally? Cell Mol Immunol. 15:335–345. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liubomirski Y, Lerrer S, Meshel T, Rubinstein-Achiasaf L, Morein D, Wiemann S, Körner C and Ben-Baruch A: Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triple-negative breast cancer. Front Immunol. 10:7572019. View Article : Google Scholar : PubMed/NCBI | |
|
Rotondi M, Coperchini F, Latrofa F and Chiovato L: Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player? Front Endocrinol (Lausanne). 9:3142018. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Mazidi S, Alotaibi M, Nedjadi T, Chaudhary A, Alzoghaibi M and Djouhri L: Blocking of cytokines signalling attenuates evoked and spontaneous neuropathic pain behaviours in the paclitaxel rat model of chemotherapy-induced neuropathy. Eur J Pain. 22:810–821. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Khazali AS, Clark AM and Wells A: Inflammatory cytokine IL-8/CXCL8 promotes tumour escape from hepatocyte-induced dormancy. Br J Cancer. 118:566–576. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J and Wang X, Wang Y, Li S and Wang X: Krüppel like factor 6 splice variant 1 (KLF6-SV1) overexpression recruits macrophages to participate in lung cancer metastasis by up-regulating TWIST1. Cancer Biol Ther. 20:680–691. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li F, Kitajima S, Kohno S, Yoshida A, Tange S, Sasaki S, Okada N, Nishimoto Y, Muranaka H, Nagatani N, et al: Retinoblastoma inactivation induces a protumoral microenvironment via enhanced CCL2 secretion. Cancer Res. 79:3903–3915. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng Y, Li H, Deng Y, Tai Y, Zeng K, Zhang Y, Liu W, Zhang Q and Yang Y: Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis. 9:4222018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Yu Y, Zhou L, Ma J, Tang K, Xu P, Ji T, Liang X, Lv J, Dong W, et al: Circulating tumor microparticles promote lung metastasis by reprogramming inflammatory and mechanical niches via a macrophage-dependent pathway. Cancer Immunol Res. 6:1046–1056. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Jin G, Qian J, Yang H, Tang H, Meng X and Li Y: Digital gene expression profiling analysis and its application in the identification of genes associated with improved response to neoadjuvant chemotherapy in breast cancer. World J Surg Oncol. 16:822018. View Article : Google Scholar : PubMed/NCBI | |
|
Mano Y, Yoshio S, Shoji H, Tomonari S, Aoki Y, Aoyanagi N, Okamoto T, Matsuura Y, Osawa Y, Kimura K, et al: Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma. J Gastroenterol. 54:1007–1018. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bedini N, Cicchetti A, Palorini F, Magnani T, Zuco V, Pennati M, Campi E, Allavena P, Pesce S, Villa S, et al: Evaluation of mediators associated with the inflammatory response in prostate cancer patients undergoing radiotherapy. Dis Markers. 2018:91281282018. View Article : Google Scholar : PubMed/NCBI | |
|
Heiskala M, Leidenius M, Joensuu K and Heikkila P: High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer. Virchows Arch. 474:3–12. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Izumi K and Mizokami A: Suppressive role of androgen/androgen receptor signaling via chemokines on prostate cancer cells. J Clin Med. 8:E3542019. View Article : Google Scholar : PubMed/NCBI | |
|
Natsagdorj A, Izumi K, Hiratsuka K, Machioka K, Iwamoto H, Naito R, Makino T, Kadomoto S, Shigehara K, Kadono Y, et al: CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. Cancer Sci. 110:279–288. 2019.PubMed/NCBI | |
|
Wang X, Yang X, Tsai Y, Yang L, Chuang KH, Keng PC, Lee SO and Chen Y: IL-6 mediates macrophage infiltration after irradiation via up-regulation of CCL2/CCL5 in non-small cell lung cancer. Radiat Res. 187:50–59. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
He S and Zhang X: The rs1024611 in the CCL2 gene and risk of gynecological cancer in Asians: A meta-analysis. World J Surg Oncol. 16:342018. View Article : Google Scholar : PubMed/NCBI | |
|
Guan X, Liu Z, Zhang J and Jin X: Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors. Adv Clin Exp Med. 27:947–953. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Amann B, Perabo FG, Wirger A, Hugenschmidt H and Schultze-Seemann W: Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br J Urol. 82:118–121. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Saik OV, Nimaev VV, Usmonov DB, Demenkov PS, Ivanisenko TV, Lavrik IN and Ivanisenko VA: Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem. BMC Med Genomics. 12 (Suppl 2):S472019. View Article : Google Scholar | |
|
Roblek M, Protsyuk D, Becker PF, Stefanescu C, Gorzelanny C, Glaus Garzon JF, Knopfova L, Heikenwalder M, Luckow B, Schneider SW and Borsig L: CCL2 is a vascular permeability factor inducing CCR2-dependent endothelial retraction during lung metastasis. Mol Cancer Res. 17:783–793. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yumimoto K, Sugiyama S, Mimori K and Nakayama KI: Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents. Cancer Sci. 110:2090–2099. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli C, Carcangiu ML, Sfondrini L, Balsari A and Tagliabue E: HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. Oncoimmunology. 8:e15129422019. View Article : Google Scholar : PubMed/NCBI | |
|
Song M, Sasazuki S, Camargo MC, Shimazu T, Charvat H, Yamaji T, Sawada N, Kemp TJ, Pfeiffer RM, Hildesheim A, et al: Circulating inflammatory markers and colorectal cancer risk: A prospective case-cohort study in Japan. Int J Cancer. 143:2767–2776. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Grossman JG, Nywening TM, Belt BA, Panni RZ, Krasnick BA, DeNardo DG, Hawkins WG, Goedegebuure SP, Linehan DC and Fields RC: Recruitment of CCR2+ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer. Oncoimmunology. 7:e14707292018. View Article : Google Scholar : PubMed/NCBI | |
|
Coniglio SJ: Role of tumor-derived chemokines in osteolytic bone metastasis. Front Endocrinol (Lausanne). 9:3132018. View Article : Google Scholar : PubMed/NCBI | |
|
Bauer D, Redmon N, Mazzio E and Soliman KF: Apigenin inhibits TNFalpha/IL-1alpha-induced CCL2 release through IKBK-epsilon signaling in MDA-MB-231 human breast cancer cells. PLoS One. 12:e01755582017. View Article : Google Scholar : PubMed/NCBI | |
|
Mazzio EA, Lewis CA and Soliman KFA: Transcriptomic profiling of MDA-MB-231 cells exposed to boswellia serrata and 3-O-acetyl-B-boswellic acid; ER/UPR mediated programmed cell death. cancer genomics proteomics. 14:409–425. 2017.PubMed/NCBI | |
|
Garlapati C, Joshi S, Sahoo B, Kapoor S and Aneja R: The persisting puzzle of racial disparity in triple negative breast cancer: Looking through a new lens. Front Biosci (Schol Ed). 11:75–88. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Newman LA, Jenkins B, Chen Y, Oppong JK, Adjei E, Jibril AS, Hoda S, Cheng E, Chitale D, Bensenhaver JM, et al: Hereditary susceptibility for triple negative breast cancer associated with western sub-saharan african ancestry: Results from an international surgical breast cancer collaborative. Ann Surg. 270:484–492. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hossain F, Danos D, Prakash O, Gilliland A, Ferguson TF, Simonsen N, Leonardi C, Yu Q, Wu XC, Miele L and Scribner R: Neighborhood social determinants of triple negative breast cancer. Front Public Health. 7:182019. View Article : Google Scholar : PubMed/NCBI | |
|
Jiagge E, Jibril AS, Davis M, Murga-Zamalloa C, Kleer CG, Gyan K, Divine G, Hoenerhoff M, Bensenhave J, Awuah B, et al: Androgen receptor and ALDH1 expression among internationally diverse patient populations. J Glob Oncol. 4:1–8. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bassey-Archibong BI, Hercules SM, Rayner LGA, Skeete DHA, Smith Connell SP, Brain I, Daramola A, Banjo AAF, Byun JS, Gardner K, et al: Kaiso is highly expressed in TNBC tissues of women of African ancestry compared to Caucasian women. Cancer Causes Control. 28:1295–1304. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Telonis AG and Rigoutsos I: Race disparities in the contribution of miRNA isoforms and tRNA-derived fragments to triple-negative breast cancer. Cancer Res. 78:1140–1154. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Torres-Luquis O, Madden K, N'Dri N M, Berg R, Olopade OF, Ngwa W, Abuidris D, Mittal S, Lyn-Cook B and Mohammed SI: LXR/RXR pathway signaling associated with triple-negative breast cancer in African American women. Breast Cancer (Dove Med Press). 11:1–12. 2018.PubMed/NCBI | |
|
Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y and Vadgama J: Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget. 9:33912–33930. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Y, Sarkissyan M, Clayton S, Chlebowski R and Vadgama JV: Association of vitamin D3 Level with breast cancer risk and prognosis in African-American and hispanic women. Cancers (Basel). 9:E1442017. View Article : Google Scholar : PubMed/NCBI | |
|
Ma H, Ursin G, Xu X, Lee E, Togawa K, Duan L, Lu Y, Malone KE, Marchbanks PA, McDonald JA, et al: Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: A pooled analysis. Breast Cancer Res. 19:62017. View Article : Google Scholar : PubMed/NCBI | |
|
Siddharth S and Sharma D: Racial disparity and triple-negative breast cancer in African-American women: A multifaceted affair between obesity, biology, and socioeconomic determinants. Cancers (Basel). 10:E5142018. View Article : Google Scholar : PubMed/NCBI | |
|
Dietze EC, Chavez TA and Seewaldt VL: Obesity and triple-negative breast cancer: Disparities, controversies, and biology. Am J Pathol. 188:280–290. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao X, Qu J, Sun Y, Wang J, Liu X, Wang F, Zhang H, Wang W, Ma X, Gao X and Zhang S: Prognostic significance of tumor-associated macrophages in breast cancer: A meta-analysis of the literature. Oncotarget. 8:30576–30586. 2017.PubMed/NCBI | |
|
Jeong H, Hwang I, Kang SH, Shin HC and Kwon SY: Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. J Breast Cancer. 22:38–51. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Valeta-Magara A, Gadi A, Volta V, Walters B, Arju R, Giashuddin S, Zhong H and Schneider RJ: Inflammatory breast cancer promotes development of M2 tumor-associated macrophages and cancer mesenchymal cells through a complex chemokine network. Cancer Res. 79:3360–3371. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang N, Liu W, Zheng Y, Wang S, Yang B, Li M, Song J, Zhang F, Zhang X, Wang Q and Wang Z: CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling. Cell Death Dis. 9:8802018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Zheng H, Li Q, Li S, Lai H, Song E, Li D and Chen J: Discovery of CCL18 antagonist blocking breast cancer metastasis. Clin Exp Metastasis. 36:243–255. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Little AC, Pathanjeli P, Wu Z, Bao L, Goo LE, Yates JA, Oliver CR, Soellner MB and Merajver SD: IL-4/IL-13 stimulated macrophages enhance breast cancer invasion via Rho-GTPase regulation of synergistic VEGF/CCL-18 signaling. Front Oncol. 9:4562019. View Article : Google Scholar : PubMed/NCBI | |
|
Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, et al: Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 35:588–602.e510. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta S, Jain A, Syed SN, Pflüger-Müller B, Leisegang MS, Weigert A, Brandes RP, Ebersberger I, Brüne B and Namgaladze D: IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors. Oncoimmunology. 7:e14941102018. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Ye J, Huang C, Yan Y and Li J: M2 macrophage-derived IL6 mediates resistance of breast cancer cells to hedgehog inhibition. Toxicol Appl Pharmacol. 364:77–82. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tandon I and Sharma NK: Macrophage flipping from foe to friend: A matter of interest in breast carcinoma heterogeneity driving drug resistance. Curr Cancer Drug Targets. 19:189–198. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sudhakaran M, Sardesai S and Doseff AI: Flavonoids: New frontier for immuno-regulation and breast cancer control. Antioxidants (Basel). 8:E1032019. View Article : Google Scholar : PubMed/NCBI | |
|
Han R, Gu S, Zhang Y, Luo A, Jing X, Zhao L, Zhao X and Zhang L: Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-κB signaling. Sci Rep. 8:95752018. View Article : Google Scholar : PubMed/NCBI | |
|
Dutta P, Sarkissyan M, Paico K, Wu Y and Vadgama JV: MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. Breast Cancer Res Treat. 170:477–486. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yao M, Fang W, Smart C, Hu Q, Huang S, Alvarez N, Fields P and Cheng N: CCR2 chemokine receptors enhance growth and cell-cycle progression of breast cancer cells through SRC and PKC Activation. Mol Cancer Res. 17:604–617. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ling Z, Yang X, Chen X, Xia J, Cheng B and Tao X: CCL2 promotes cell migration by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. J Oral Pathol Med. 48:477–482. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu W, Wei Q, Han M, Zhou B, Wang H, Zhang J, Wang Q, Sun J, Feng L, Wang S, et al: CCL2-SQSTM1 positive feedback loop suppresses autophagy to promote chemoresistance in gastric cancer. Int J Biol Sci. 14:1054–1066. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang T, Zhan Q, Peng X, Qiu Z and Zhao T: CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel. Oncol Lett. 16:1267–1274. 2018.PubMed/NCBI | |
|
Sarin N, Engel F, Rothweiler F, Cinatl J, Michaelis M, Frötschl R, Fröhlich H and Kalayda GV: Key players of cisplatin resistance: towards a systems pharmacology approach. Int J Mol Sci. 19:E7672018. View Article : Google Scholar : PubMed/NCBI | |
|
Regan DP, Coy JW, Chahal KK, Chow L, Kurihara JN, Guth AM, Kufareva I and Dow SW: The angiotensin receptor blocker losartan suppresses growth of pulmonary metastases via AT1R-independent inhibition of CCR2 signaling and monocyte recruitment. J Immunol. 202:3087–3102. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Zhong H, Chu T, Zhang X, Li R, Sun J, Zhong R, Yang Y, Alam MS, Lou Y, et al: Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur Respir J. 53:18015622019. View Article : Google Scholar : PubMed/NCBI | |
|
Yao Z, Zhang J, Zhang B, Liang G, Chen X, Yao F, Xu X, Wu H, He Q, Ding L and Yang B: Imatinib prevents lung cancer metastasis by inhibiting M2-like polarization of macrophages. Pharmacol Res. 133:121–131. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Wang SH, Chen SC, Chen CY and Lin TM: Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells. BMC Cancer. 19:1762019. View Article : Google Scholar : PubMed/NCBI | |
|
Ku WT, Tung JJ, Lee TJ and Lai KC: Long-term exposure to oroxylin a inhibits metastasis by suppressing CCL2 in oral squamous cell carcinoma Cells. Cancers (Basel). 11:E3532019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang D, Yue DL, Wang D, Chen XF, Yin XY, Wang YP, Yang L and Zhang Y: Aspirin inhibits cell stemness of esophageal cancer by downregulation of chemokine CCL2. Zhonghua Zhong Liu Za Zhi. 40:744–749. 2018.(In Chinese). PubMed/NCBI | |
|
Iwamoto H, Izumi K, Natsagdorj A, Naito R, Makino T, Kadomoto S, Hiratsuka K, Shigehara K, Kadono Y, Narimoto K, et al: Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells. Prostate. 79:468–479. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ishii N, Araki K, Yokobori T, Hagiwara K, Gantumur D, Yamanaka T, Handa T, Tsukagoshi M, Igarashi T, Watanabe A, et al: Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Cancer Sci. 110:334–344. 2019.PubMed/NCBI | |
|
Shen H, He M, Lin R, Zhan M, Xu S, Huang X, Xu C, Chen W, Yao Y, Mohan M and Wang J: PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway. J Exp Clin Cancer Res. 38:2472019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou L, Jiang Y, Liu X, Li L, Yang X, Dong C, Liu X, Lin Y, Li Y, Yu J, et al: Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-κB-CCL2 signaling in lung cancer. Oncogene. 38:5792–5804. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ding M, He SJ and Yang J: MCP-1/CCL2 Mediated by autocrine loop of PDGF-BB promotes invasion of lung cancer cell by recruitment of macrophages via CCL2-CCR2 axis. J Interferon Cytokine Res. 39:224–232. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tong J, Shen Y, Zhang Z, Hu Y, Zhang X and Han L: Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway. Biosci Rep. 39:BSR201904522019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HH, Jung J, Moon A, Kang H and Cho H: Antitumor and anti-invasive effect of apigenin on human breast carcinoma through suppression of IL-6 expression. Int J Mol Sci. 20:E31432019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu M, Li D, Yang C and Ji JS: MicroRNA-34a inhibition of the TLR signaling pathway Via CXCL10 suppresses breast cancer cell invasion and migration. Cell Physiol Biochem. 46:1286–1304. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Chen J, Guan GW, Zhang T, Lu FM and Chen XM: Expression and clinical significance of chemokine CXCL10 and its receptor CXCR3 in hepatocellular carcinoma. Beijing Da Xue Xue Bao Yi Xue Ban. 51:402–408. 2019.(In Chinese). PubMed/NCBI | |
|
Guo J, Xiao Y, Iyer R, Lu X, Lake M, Ladror U, Harlan J, Samanta T, Tomlinson M, Bukofzer G, et al: Empowering therapeutic antibodies with IFN-α for cancer immunotherapy. PLoS One. 14:e02198292019. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Y, Yuan L, Lu Q, Xu H and He X: Distinctive profiles of tumor-infiltrating immune cells and association with intensity of infiltration in colorectal cancer. Oncol Lett. 15:3876–3882. 2018.PubMed/NCBI | |
|
Fang S, Xu T, Xiong M, Zhou X, Wang Y, Haydu LE, Ross MI, Gershenwald JE, Prieto VG, Cormier JN, et al: Role of immune response, inflammation, and tumor immune response-Related cytokines/chemokines in melanoma progression. J Invest Dermatol. 139:2352–2358.e3. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Nieto JC, Zamora C, Porcel JM, Mulet M, Pajares V, Muñoz-Fernandez AM, Calvo N, Espinosa I, Pascual-García M, Bielsa S and Vidal S: Migrated T lymphocytes into malignant pleural effusions: An indicator of good prognosis in lung adenocarcinoma patients. Sci Rep. 9:29962019. View Article : Google Scholar : PubMed/NCBI | |
|
Kang SH, Keam B, Ahn YO, Park HR, Kim M, Kim TM, Kim DW and Heo DS: Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma. Oncoimmunology. 8:e15150572019. View Article : Google Scholar : PubMed/NCBI | |
|
Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H and Lenz HJ: CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation-A target for novel cancer therapy. Cancer Treat Rev. 63:40–47. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Morrison K, Challita-Eid PM, Raitano A, An Z, Yang P, Abad JD, Liu W, Lortie DR, Snyder JT, Capo L, et al: Development of ASG-15ME, a novel antibody-drug conjugate targeting SLITRK6, a new urothelial cancer biomarker. Mol Cancer Ther. 15:1301–1310. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lin JK, Chen YC, Huang YT and Lin-Shiau SY: Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J Cell Biochem Suppl. 28-29:39–48. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M and Gao J: Targeting advanced urothelial carcinoma-developing strategies. Curr Opin Oncol. 31:207–215. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sanford T, Porten S and Meng MV: Molecular analysis of upper tract and bladder urothelial carcinoma: Results from a microarray comparison. PLoS One. 10:e01371412015. View Article : Google Scholar : PubMed/NCBI | |
|
Birt DF, Walker B, Tibbels MG and Bresnick E: Anti-mutagenesis and anti-promotion by apigenin, robinetin and indole-3-carbinol. Carcinogenesis. 7:959–963. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Birt DF, Mitchell D, Gold B, Pour P and Pinch HC: Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Anticancer Res. 17:85–91. 1997.PubMed/NCBI | |
|
Sharma A, Ghani A, Sak K, Tuli HS, Sharma AK, Setzer WN, Sharma S and Das AK: Probing into therapeutic anti-cancer potential of apigenin: Recent trends and future directions. recent pat inflamm Allergy Drug Discov. Aug 16–2019.doi: 10.2174/1872213X13666190816160240 (Epub ahead of print). View Article : Google Scholar | |
|
Ginwala R, Bhavsar R, Chigbu DI, Jain P and Khan ZK: Potential role of flavonoids in treating chronic inflammatory diseases with a special focus on the anti-inflammatory activity of apigenin. Antioxidants (Basel). 8:E352019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Tian D, Liao X, Zhang Y, Xiao J, Chen W, Liu Q, Chen Y, Li D, Zhu L and Cai S: Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1α, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-mutated H1975 cells. Front Pharmacol. 10:2602019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Xu H, Yu X, Wang X, Zhu X and Xu X: Apigenin inhibits in vitro and in vivo tumorigenesis in cisplatin-resistant colon cancer cells by inducing autophagy, programmed cell death and targeting m-TOR/PI3K/Akt signalling pathway. J BUON. 24:488–493. 2019.PubMed/NCBI | |
|
Gao AM, Zhang XY, Hu JN and Ke ZP: Apigenin sensitizes hepatocellular carcinoma cells to doxorubic through regulating miR-520b/ATG7 axis. Chem Biol Interact. 280:45–50. 2018. View Article : Google Scholar : PubMed/NCBI |
